IP Library Granted Patent US 8,105,580
Granted Patent B2
US 8,105,580 · App. 10/884,860 · Granted Jan 31, 2012

Methods of using adipose derived stem cells to promote wound healing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,105,580
App. No.
10/884,860
Granted
Jan 31, 2012
Kind
B2
Abstract

Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

Claims (48)

1. A method of accelerating the healing of a wound of the skin of a subject, comprising:

identifying a subject having a wound of the skin; and

providing adipose tissue to a self contained adipose-derived stem cell processing unit comprising:

a tissue collecting container configured to receive and fully or partially disaggregate adipose tissue, wherein said tissue collecting container is coupled to a cell collection container wherein said coupling defines a closed system in which said fully or partially disaggregated adipose tissue directed from tissue collecting container to cell collection container is not exposed to the external environment; and wherein said cell collection container, further comprises a cell concentrator that facilitates separation of the cells in a suspension; and

an outlet that is structured to permit said concentrated population of cells comprising adipose-derived cells to be removed from said stem cell processing unit;

obtaining a concentrated population of cells comprising adipose-derived stem cells from said self contained adipose-derived stem cell processing unit; and

providing said concentrated population of cells comprising adipose-derived stem cells to said subject in an amount sufficient to accelerate the healing of said wound.

2. The method of claim 1 , wherein said subject is a diabetic.

3. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without further purification.

4. The method of claim 1 , wherein the wound is a non healing diabetic wound.

5. The method of claim 3 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without culturing the cells before administering them to said subject.

6. The method of claim 1 , wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the subject.

7. The method of claim 1 , further comprising providing an additive to said concentrated population of cells comprising adipose-derived stem cells.

8. A method of accelerating the healing of a wound of the skin of a subject, comprising:

identifying a subject having a wound of the skin; and

providing adipose tissue to a self contained adipose-derived stem cell processing unit comprising:

a tissue collection chamber that is configured to receive a first portion of unprocessed adipose tissue from said subject while maintaining a closed system, wherein said tissue collection chamber comprises an aspiration port structured to be coupled to a suction device;

a first filter that is disposed within said tissue collection chamber, wherein said first filter is configured to retain a first component of said unprocessed adipose tissue and pass a second component of said unprocessed adipose tissue, such that said first filter substantially separates said first component from said second component, and wherein said first component comprises a cell population that comprises adipose-derived stem cells and said second component comprises lipid, blood, mature adipocytes and saline;

a processing chamber that is joined to said tissue collection chamber by a conduit such that a closed system is maintained, wherein said processing chamber comprises a second filter, a centrifuge, or a spinning membrane filter;

a programmable processing device capable of communication with said tissue collection chamber and said processing chamber, wherein said processing device operates at least one pump configured to use pressure to control ingress and egress of tissues through said automated adipose-derived stem cell processing unit; and

an outlet wherein said outlet is configured to allow the aseptic removal of a concentrated population of cells comprising adipose-derived stem cells obtained from said processing chamber;

obtaining a concentrated population of cells comprising adipose-derived stem cells from said self contained adipose-derived stem cell processing unit; and

providing said concentrated population of cells comprising adipose-derived stem cells to said subject in an amount sufficient to accelerate the healing of said wound.

9. The method of claim 8 , wherein said subject is a diabetic.

10. The method of claim 8 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without further purification.

11. The method of claim 8 , wherein the wound is a non healing diabetic wound.

12. The method of claim 10 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject without culturing the cells before administering them to said subject.

13. The method of claim 8 , wherein the concentrated population of cells comprising adipose-derived stem cells is grown in cell culture prior to being provided to the subject.

14. The method of claim 8 , further comprising providing an additive to said concentrated population of cells comprising adipose-derived stem cells.

15. The method of claim 14 , wherein said additive comprises one or more angiogenic factors.

16. The method of claim 1 , wherein the concentrated population of cells comprising adipose-derived stem cells further comprises adipose-derived progenitor cells.

17. The method of claim 8 , wherein the concentrated population of cells comprising adipose-derived stem cells further comprises adipose-derived progenitor cells.

18. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a bolus.

19. The method of claim 8 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a bolus.

20. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a multiple doses.

21. The method of claim 8 , wherein said concentrated population of cells comprising adipose-derived stem cells is provided to said subject in a multiple doses.

22. The method of claim 7 , wherein said additive is an immunosuppressive agent.

23. The method of claim 14 , wherein said additive is an immunosuppressive agent.

24. The method of claim 1 , wherein at least a portion of said concentrated population of cells comprising adipose-derived stem cells is provided directly to the wound of the skin.

25. The method of claim 8 , wherein at least a portion of said concentrated population of cells comprising adipose-derived stem cells is provided directly to the wound of the skin.

26. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells is derived from adipose tissue from said subject.

27. The method of claim 8 , wherein said concentrated population of cells comprising adipose-derived stem cells is derived from adipose tissue from said subject.

28. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells comprises at least about 1×10 5 to about 1×10 7 cells/mL.

29. The method of claim 8 , wherein said concentrated population of cells comprising adipose-derived stem cells comprises at least about 1×10 5 to about 1×10 7 cells/mL.

30. The method of claim 1 , wherein said cell concentrator is a centrifuge.

31. The method of claim 30 , wherein said centrifuge is disposed within said cell collection container.

32. The method of claim 8 , wherein said processing chamber comprises a centrifuge.

33. The method of claim 32 , wherein said centrifuge is disposed within said processing chamber.

Assignments (11)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 049313 FRAME: 0434. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 1, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049942/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049313/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049651/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2019
From: OXFORD FINANCE LLC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 049011/0347 →
SECURITY INTEREST Recorded Sep 22, 2017
From: CYTORI THERAPEUTICS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 043952/0150 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2015
From: OXFORD FINANCE LLC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 035902/0191 →
RELEASE OF SECURITY INTEREST Recorded Jul 3, 2013
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 030734/0778 →
SECURITY AGREEMENT Recorded Jun 28, 2013
From: CYTORI THERAPEUTICS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 030715/0625 →
SECURITY AGREEMENT Recorded Dec 3, 2012
From: CYTORI THERAPEUTICS INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 029395/0660 →
MERGER Recorded Mar 17, 2006
From: MACROPORE BIOSURGERY, INC.
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 017350/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2004
From: FRASER, JOHN K.; HEDRICK, MARC H.; DANIELS, ERIC
To: MACROPORE BIOSURGERY, INC.
Reel/Frame 015985/0497 →